Bafna Pharmaceuticals Q4 FY26 Results Preview: Revenue, PAT & EBITDA Growth Expectations
- March 13, 2026
- Posted by: Neeraj Pandey
- Category: News
Bafna Pharmaceuticals Q4 FY26 results date is all set to be announced soon and most investors are awaiting it. Professionals are expecting an increase in revenue due to higher sales and a significant rise in PAT. Bafna Pharmaceuticals was listed on the National Stock Exchange (NSE) on 27-Feb-2020. Bafna Pharmaceuticals share has its face value of 10 per share, and its NSE symbol is BAFNAPH. The company operates in the Healthcare sector and primarily belongs to the Pharmaceuticals industry.
Bafna Pharmaceuticals Q4 Results 2026 Preview
- Bafna Pharmaceuticals Q4 FY26 revenue is expected to be around Stable Performance, representing a 14% YoY increase compared to the same quarter last year.
- Profit After Tax, or PAT, is projected to rise 14% YoY.
- EBITDA to rise 8%.
- Bafna Pharmaceuticals is expected to show Stable Performance in its revenue.
Click and Sign Up to Get Live Updates on Q4 Results
Bafna Pharmaceuticals Share Performance
- Over the past six months, Bafna Pharmaceuticals share price has negative by -3% to 104.79.
- Moreover, over the past year, the stock has positive by 4%
- Despite this weak short-term performance, Bafna Pharmaceuticals stock has delivered a financially sound 51% return over the past 5 years.
- As of today, 13-03-2026, the Bafna Pharmaceuticals share price is trading at 104.79 per share.
Key Factors to Watch for Bafna Pharmaceuticals Q4 Results FY26
- Revenue Growth & Segment Performance – Focus on topline growth in the Pharmaceuticals industry within the Healthcare sector.
- Occupancy Levels & Seat Expansion – Monitor operational expansion and capacity utilisation trends.
- Profitability & Margin Trends – Track EBITDA and PAT margins to evaluate cost control and operating efficiency.
- Order Book & New Client Wins – Watch for updates on new contracts, partnerships, and long-term deals.
- Balance Sheet & Cash Flow Position – Review debt levels, working capital management, and operating cash flows for financial stability.
About Bafna Pharmaceuticals
Bafna Pharmaceuticals operates in the healthcare segment and focuses on expanding its product portfolio, improving operational efficiency, and strengthening distribution across domestic and export markets. The company continues to focus on growth through innovation, capacity expansion, and improving margins while maintaining a strong presence in its core business segments.
Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!
Final Thoughts
Bafna Pharmaceuticals is gear up to announce its Q4 FY26 results. Analysts expect 14% revenue growth, a 14% rise in PAT, and a 8% rise in EBITDA. Bafna Pharmaceuticals focuses on revenue growth from order execution, margin improvement, a strong order book, and management.
Stay informed with Univest blogs to get real-time updates on Bafna Pharmaceuticals Q4 results FY26.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Recent Articles
Advent Hotels International Q4 FY26 Results Preview
Advani Hotels Q4 FY26 Results Preview & Outlook
Advance Agrolife Q4 FY26 Results Preview & Outlook
Advait Energy Transitions Q4 FY26 Results Preview
